Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex N Bullock

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Cell Reports|February 9, 2018
CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary FunctionPeter Canning, Kwangjin Park, João Gonçalves, et al.
BMC Musculoskeletal Disorders|June 1, 2022
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)Bernard J Smilde, Clemens Stockklausner, Richard Keen, et al.
The Journal of Biological Chemistry|October 30, 2010
Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligaseFahad Zadjali, Ashley C W Pike, Mattias Vesterlund, et al.
Journal of Molecular Biology|June 22, 2010
Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4Panagis Filippakopoulos, Andrew Low, Timothy D Sharpe, et al.
Plos One|March 31, 2009
Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patientsKirsten A Petrie, Wen Hwa Lee, Alex N Bullock, et al.
Chemistry & Biology|February 1, 2011
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicingOleg Fedorov, Kilian Huber, Andreas Eisenreich, et al.
Scientific Reports|January 3, 2024
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivoElizabeth J Brown, Leire Balaguer-Lluna, Adam P Cribbs, et al.
Cell Death and Differentiation|April 5, 2022
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradationZhuoyao Chen, Rafael M Ioris, Stacey Richardson, et al.
Nature Communications|April 2, 2025
Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitmentZhuoyao Chen, Gamma Chi, Timea Balo, et al.
European Journal of Medicinal Chemistry|June 8, 2020
Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffoldChalada Suebsuwong, Bing Dai, Daniel M Pinkas, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Cell Reports|February 9, 2018
CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary FunctionPeter Canning, Kwangjin Park, João Gonçalves, et al.
BMC Musculoskeletal Disorders|June 1, 2022
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)Bernard J Smilde, Clemens Stockklausner, Richard Keen, et al.
The Journal of Biological Chemistry|October 30, 2010
Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligaseFahad Zadjali, Ashley C W Pike, Mattias Vesterlund, et al.
Journal of Molecular Biology|June 22, 2010
Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4Panagis Filippakopoulos, Andrew Low, Timothy D Sharpe, et al.
Plos One|March 31, 2009
Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patientsKirsten A Petrie, Wen Hwa Lee, Alex N Bullock, et al.
Chemistry & Biology|February 1, 2011
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicingOleg Fedorov, Kilian Huber, Andreas Eisenreich, et al.
Scientific Reports|January 3, 2024
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivoElizabeth J Brown, Leire Balaguer-Lluna, Adam P Cribbs, et al.
Cell Death and Differentiation|April 5, 2022
Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradationZhuoyao Chen, Rafael M Ioris, Stacey Richardson, et al.
Nature Communications|April 2, 2025
Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitmentZhuoyao Chen, Gamma Chi, Timea Balo, et al.
European Journal of Medicinal Chemistry|June 8, 2020
Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffoldChalada Suebsuwong, Bing Dai, Daniel M Pinkas, et al.
Pageof 12